Pharmacologic treatment of spasticity in children

Seminars in Pediatric Neurology

Volumn 17, Issue 4, 2010, Pages 261-267

  Tilton, Ann ^a   Vargus Adams, Jilda ^b   Delgado, Mauricio R ^c  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BACLOFEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; PHENOL; PLACEBO; TIZANIDINE;

ANOREXIA; ATAXIA; BODY POSTURE; CHILD; CLINICAL TRIAL; COORDINATION DISORDER; DENERVATION; DIARRHEA; DIZZINESS; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSPHAGIA; FATIGUE; HUMAN; HYPERSALIVATION; HYPOTENSION; INCONTINENCE; INJECTION SITE PAIN; IRRITABILITY; LIVER TOXICITY; LOW DRUG DOSE; NEUROLYSIS; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR ELECTRICAL STIMULATION; NONHUMAN; PARESTHESIA; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SPASTICITY; TREATMENT DURATION; VOMITING; WEAKNESS; XEROSTOMIA;

AGE FACTORS; BACLOFEN; BOTULINUM TOXINS; CHILD; CLONIDINE; DANTROLENE; DIAZEPAM; HUMANS; INJECTIONS, SPINAL; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS;

EID: 78650290311     PISSN: 10719091     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.spen.2010.10.009     Document Type: Review

References (64)

1. Sanger T.D., Delgado M.R., Gaebler-Spira D., et al. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003, 111:e89-e97.
2. Lance J.W. Pyramidal and extrapyramidal disorders. Electromyography in CNS Disorders 1984, 1-19. Butterworth, Boston, MA. E.M.G. Central (Ed.).
3. Delgado M.R., Albright A.L. Movement disorders in children: Definitions, classifications, and grading systems. J Child Neurol 18 suppl 2003, 1(suppl 1):S1-S8.
4. Yeargin-Allsopp M., Van Naarden Braun K., Doernberg N.S., et al. Prevalence of cerebral palsy in 8 year old children in three areas of the United States in 2002: A multisite collaboration. Pediatrics 2008, 121:547-554.
5. Krach L.E. Pharmacotherapy of spasticity: Oral medications and intrathecal baclofen. J Child Neurol 2001, 16:31-36.
6. Damiano D.L., Quinlivan J., Owen B.F., et al. Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function. Eur J Neurol 2001, 8(suppl 5):40-49.
7. Gorter J.W., Verschuren O., van Riel L., et al. The relationship between spasticity in young children (18 months of age) with cerebral palsy and their gross motor function development. BMC Musculoskelet Disord 2009, 10:108.
8. Ashworth B. Preliminary Trial of carisoprodol in multiple sclerosis. Practitioner 1964, 192:540-542.
9. Bohannon R.W., Smith M.B. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987, 67:206-207.
10. Nielsen J.F., Sinkjaer T. A comparison of clinical and laboratory measures of spasticity. Mult Scler 1996, 1:296-301.
11. Fleuren J.F., Voerman G.E., Erren-Wolters C.V., et al. Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 2010, 81:46-52.
12. Gracies J.M., Burke K., Clegg N.J., et al. Reliability of the Tardieu Scale for assessing spasticity in children with cerebral palsy. Arch Phys Med Rehabil 2010, 91:421-428.
13. Milla P.J., Jackson A.D. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977, 5:398-404.
14. Scheinberg A., Hall K., Lam L.T., et al. Oral baclofen in children with cerebral palsy: A double-blind cross-over pilot study. J Paediatr Child Health 2006, 42:715-720.
15. Olesch C.A., Greaves S., Imms C., et al. Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: A randomized controlled trial. Dev Med Child Neurol 2010, 52:79-86.
16. Mayer NH E.A., Childers M.K. Common patterns of clinical motor dysfunction. Spasticity and Other Forms of Muscle Overactivity in the Upper Motor Neuron Syndrome: Etiology, Evaluation, Management, and the Role of Botulinum Toxin 2008, 27-38. WE MOVE, NY, New York, A. M.N. Brashear (Ed.).
17. Tardieu G., Tardieu C., Hariga J., et al. Treatment of spasticity in injection of dilute alcohol at the motor point or by epidural route. Clinical extension of an experiment on the decerebrate cat. Dev Med Child Neurol 1968, 10:555-568.
18. Spira R. Management of spasticity in cerebral palsied children by peripheral nerve block with phenol. Dev Med Child Neurol 1971, 13:164-173.
19. Yadav S.L., Singh U., Dureja G.P., et al. Phenol block in the management of spastic cerebral palsy. Indian J Pediatr 1994, 61:249-255.
20. Delgado M.R., Delgado M.R., Hirtz D., et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2010, 74:336-343.
21. Sanger TD K.S., Sherman-Levine S. Botulinum toxin type B improves the speed of reaching in children with cerebral palsy and arm dystonia: An open-label, dose-escalation pilot study. J Child Neurol 2007, 22:116-122.
22. Gooch J.L., Patton C.P. Combining botulinum toxin and phenol to manage spasticity in children. Arch Phys Med Rehabil 2004, 85:1121-1124.
23. Dressler D., Eleopra R. Clinical use of non-A. botulinum toxins: Botulinum toxin type B. Neurotox Res 2006, 9:121-125.
24. Kawamura A., Campbell K., Lam-Damji S., et al. A randomized controlled trial comparing botulinum toxin A dosage in the upper extremity of children with spasticity. Dev Med Child Neurol 2007, 49:331-337.
25. Ackman J.D., Russman B.S., Thomas S.S., et al. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Dev Med Child Neurol 2005, 47:620-627.
26. Moore A.P., Ade-Hall R.A., Smith C.T., et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008, 71:122-128.
27. Corry I.S., Cosgrove A.P., Duffy C.M., et al. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: A randomised prospective trial. J Pediatr Orthop 1998, 18:304-311.
28. Mall V., Heinen F., Siebel A., et al. Treatment of adductor spasticity with BTX-A in children with CP: A randomized, double-blind, placebo-controlled study. Dev Med Child Neurol 2006, 48:10-13.
29. Corry I.S., Cosgrove A.P., Walsh E.G., et al. Botulinum toxin A in the hemiplegic upper limb: A double-blind trial. Dev Med Child Neurol 1997, 39:185-193.
30. Fehlings D., Rang M., Glazier J., et al. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000, 137:331-337.
31. Lowe K., Novak I., Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2006, 48:170-175.
32. Wallen M., O'Flaherty S.J., Waugh M.C. Functional outcomes of intramuscular botulinum toxin type A and occupational therapy in the upper limbs of children with cerebral palsy: A randomized controlled trial. Arch Phys Med Rehabil 2007, 88:1-10.
33. Fehlings D., Rang M., Glazier J., et al. Botulinum toxin type a injections in the spastic upper extremity of children with hemiplegia: Child characteristics that predict a positive outcome. Eur J Neurol 2001, 8(suppl 5):145-149.
34. Polak F., Morton R., Ward C., et al. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2002, 44:551-555.
35. Ubhi T., Bhakta B.B., Ives H.L., et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000, 83:481-487.
36. Steenbeek D., Meester-Delver A., Becher J.G., et al. The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: Evaluation with goal attainment scaling. Clin Rehabil 2005, 19:274-282.
37. Baker R., Jasinski M., Maciag-Tymecka I., et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: A randomized, double-blind, placebo-controlled, dose-ranging study. Dev Med Child Neurol 2002, 44:666-675.
38. Kanovsky P., Bares M., Severa S., et al. Functional benefit of botulinum toxin (Dysport) in the treatment of dynamic equinus cerebral palsy spasticity: A prospective, multicenter, double-blind, placebo-controlled study. Ces A Slov Neurol. Neuro Chir 2004, 67:16-23.
39. Simpson D.M., Gracies J.M., Graham H.K., et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691-1698.
40. Wiersma H.E., van Boxtel C.J., Butter J.J., et al. Pharmacokinetics of a single oral dose of baclofen in pediatric patients with gastroesophageal reflux disease. Ther Drug Monit 2003, 25:93-98.
41. Brunstrom-Hernandez J.E., Thio L.L., Lowenhaupt S.A., et al. Baclofen efficacy and safety trials (BEST): Lack of conscensus on oral baclofen dosing practices for children with cerebral palsy. Dev Med Child Neurol 2009, 51:43.
42. Gracies J.M., Nance P., Elovic E., et al. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl 1997, 6:S92-S120.
43. Verrotti A., Greco R., Spalice A., et al. Pharmacotherapy of spasticity in children with cerebral palsy. Pediatr Neurol 2006, 34:1-6.
44. Chou R., Peterson K., Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage 2004, 28:140-175.
45. Brin I.L., Kurenkov A.L., Gotlib V. [The use of sirdalud in cerebral palsy in children]. Zh Nevrol Psikhiatr S S Korsakova 1999, 99:30-33.
46. Vasquez-Briceno A., Arellano-Saldaña M.E., León-Hernández S.R., et al. The usefulness of tizanidine. A one-year follow-up of the treatment of spasticity in infantile cerebral palsy. Rev Neurol 2006, 43:132-136.
47. Mathew A., Mathew M.C. Bedtime diazepam enhances well-being in children with spastic cerebral palsy. Pediatr Rehabil 2005, 8:63-66.
48. Mathew A., Mathew M.C., Thomas M., et al. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr 2005, 51:109-113.
49. Nogen A.G. Medical treatment for spasticity in children with cerebral palsy. Childs Brain 1976, 2:304-308.
50. Engle H.A. The effect of diazepam (Valium) in children with cerebral palsy: A double-blind study. Dev Med Child Neurol 1966, 8:661-667.
51. Ward A., Chaffman M.O., Sorkin E.M. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986, 32:130-168.
52. Joynt R.L., Leonard J.A. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980, 22:755-767.
53. Denhoff E., Feldman S., Smith M.G., et al. Treatment of spastic cerebral-palsied children with sodium dantrolene. Dev Med Child Neurol 1975, 17:736-742.
54. Motta F., Buonaguro V., Stignani C. The use of intrathecal baclofen pump implants in children and adolescents: Safety and complications in 200 consecutive cases. J Neurosurg 2007, 107(suppl):32-35.
55. Coffey R.J., Edgar T.S., Francisco G.E., et al. Abrupt withdrawal from intrathecal baclofen: Recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002, 83:735-741.
56. Wiens H.D. Spasticity in children with cerebral palsy: A retrospective review of the effects of intrathecal baclofen. Issues Compr Pediatr Nurs 1998, 21:49-61.
57. Grabb P.A., Guin-Renfroe S., Meythaler J.M. Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery 1999, 45:833-836.
58. Awaad Y., Tayem H., Munoz S., et al. Functional assessment following intrathecal baclofen therapy in children with spastic cerebral palsy. J Child Neurol 2003, 18:26-34.
59. Bjornson K.F., McLaughlin J.F., Loeser J.D., et al. Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: A descriptive pilot study. Arch Phys Med Rehabil 2003, 84:500-506.
60. Murphy N.A., Irwin M.C., Hoff C. Intrathecal baclofen therapy in children with cerebral palsy: Efficacy and complications. Arch Phys Med Rehabil 2002, 83:1721-1725.
61. Albright A.L., Barry M.J., Fasick M.P., et al. Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity. Pediatr Neurosurg 1995, 23:82-85.
62. Van Schaeybroeck P., Nuttin B., Lagae L., et al. Intrathecal baclofen for intractable cerebral spasticity: A prospective placebo-controlled, double-blind study. Neurosurgery 2000, 46:603-609.
63. de Lissovoy G., Matza L.S., Green H., et al. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol 2007, 22:49-59.
64. McDougall J., Wright V. The ICF-CY and goal attainment Scaling: Benefits of their combined use for pediatric practice. Disabil Rehabil 2009, 31:1362-1372.